BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 20185829)

  • 41. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
    Shang D; Liu Y; Yang P; Chen Y; Tian Y
    Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
    Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J
    Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction of hepatic fibrosis by overexpression of von Hippel-Lindau protein in experimental models of chronic liver disease.
    Wang J; Lu Z; Xu Z; Tian P; Miao H; Pan S; Song R; Sun X; Zhao B; Wang D; Ma Y; Song X; Zhang S; Liu L; Jiang H
    Sci Rep; 2017 Jan; 7():41038. PubMed ID: 28112200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
    Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
    Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VHL type 2B mutations retain VBC complex form and function.
    Hacker KE; Lee CM; Rathmell WK
    PLoS One; 2008; 3(11):e3801. PubMed ID: 19030229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
    Kapitsinou PP; Haase VH
    Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
    Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
    PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
    Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
    Wolf C; Smith S; van Wijk SJL
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner.
    Kai S; Tanaka T; Daijo H; Harada H; Kishimoto S; Suzuki K; Takabuchi S; Takenaga K; Fukuda K; Hirota K
    Antioxid Redox Signal; 2012 Feb; 16(3):203-16. PubMed ID: 22004513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
    Merlo A; Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Pitiot AS; Balbín M; Astudillo A; Valdés N; Scola B; Del Toro R; Méndez-Ferrer S; Piruat JI; Suarez C; Chiara MD
    Oncotarget; 2017 Jan; 8(4):6700-6717. PubMed ID: 28036268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
    Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
    Morris MR; Hughes DJ; Tian YM; Ricketts CJ; Lau KW; Gentle D; Shuib S; Serrano-Fernandez P; Lubinski J; Wiesener MS; Pugh CW; Latif F; Ratcliffe PJ; Maher ER
    Anticancer Res; 2009 Nov; 29(11):4337-43. PubMed ID: 20032376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY; Poellinger L; Walker CL
    Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.
    Razorenova OV; Castellini L; Colavitti R; Edgington LE; Nicolau M; Huang X; Bedogni B; Mills EM; Bogyo M; Giaccia AJ
    Mol Cell Biol; 2014 Feb; 34(4):739-51. PubMed ID: 24344197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.